Investigation of the Proportion of Human Epidermal Growth Factor Receptor 2 Protein Overexpression of Gastric Adenocarcinoma and Prognostic Effect of HER2, and Analysis of Practice Pattern of Herceptin Use in Stage IV Gastric Cancer
This trial is active, not recruiting.
|Start date||May 2014|
|End date||March 2015|
|Trial size||860 participants|
|Trial identifier||NCT02136836, GSCH-STO13-01, Roche|
The objective of this study is to investigate the proportion of HER2 overexpression in gastric cancer patients group, to evaluate the relation of HER2 overexpression with prognosis, and to analyze the proportion of herceptin applied to patients in clinical field. Furthermore, the investigators are going to reevaluate the clinical benefit of Herceptin for survival prolongation compared to chemotherapy only.
The proportion of HER2 overexpression in gastric cancer patients
time frame: 8 years
Gastric cancer specific survival according to HER2 expression in each stage
time frame: 5 years
Male or female participants of any age.
Inclusion Criteria: 1. Histologically confirmed gastric adenocarcinoma 2. Patients were diagnosed during 2006-2013 3. HER2 expression status was evaluated in primary gastric cancer or metastatic lesion. Exclusion Criteria: - Patients with second primary cancer within 5 years
|Principal investigator||Jae Yong Cho, M.D.,Ph.D.|
Call for more information